Cardima submits cardiac ablation system 510(k):
This article was originally published in Clinica
Executive Summary
Cardima has submitted to the US FDA a 510(k) marketing application for a surgical ablation system for use in minimally invasive cardiac surgery. The system uses commercially available electro-surgical radiofrequency (RF) generators, a Cardima surgical probe employing multi-electrode linear array microcatheter technology, and a power-channelling device, INTELLITEMP, which allows the surgeon to apply RF energy to any or all of the individual electrodes on the probe. The Fremont, California firm said that the product was part of its "atrial fibrillation strategy" to develop less invasive tools for treating irregular heart rhythms.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.